One biotech startup, rBIO of Houston, is aiming to make insulin more affordable by producing a copycat version of the drug—known as a biosimilar. It’s not the only company developing biosimilar insulin, but it says it has invented a new process to do so using custom-made bacteria.
CEO Cameron Owen says his company has created novel strains of bacteria that can produce insulin at twice the yield than is currently possible. Thursday,
rBIO announced it had completed lab tests of its biosimilar insulin to determine that it is structurally and functionally similar to a brand-name one. It plans to begin a clinical trial later this year to determine whether its insulin works as well as a product already on the market.